

# Federico Gulluni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1295750/publications.pdf>

Version: 2024-02-01

22  
papers

2,195  
citations

567281

15  
h-index

713466

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

3590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. <i>Gut</i> , 2023, 72, 360-371.	12.1	8
2	Phosphoinositide Conversion Inactivates RAS and Drives Metastases in Breast Cancer. <i>Advanced Science</i> , 2022, 9, e2103249.	11.2	8
3	Structural basis of phosphatidylinositol 3-kinase C2 $\beta$ function. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 218-228.	8.2	14
4	Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. <i>Cancers</i> , 2021, 13, 3517.	3.7	68
5	PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation. <i>Science</i> , 2021, 374, eabk0410.	12.6	37
6	Phosphoinositides in cell proliferation and metabolism. <i>Advances in Biological Regulation</i> , 2020, 75, 100693.	2.3	14
7	PI(3,4)P2 Signaling in Cancer and Metabolism. <i>Frontiers in Oncology</i> , 2020, 10, 360.	2.8	48
8	Class II PI3K Functions in Cell Biology and Disease. <i>Trends in Cell Biology</i> , 2019, 29, 339-359.	7.9	99
9	Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. <i>PLoS Genetics</i> , 2019, 15, e1008088.	3.5	45
10	Targeting PI3K signaling in cancer: Challenges and advances. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 361-366.	7.4	54
11	Downregulation of class II phosphoinositide 3-kinase PI3K-C2 $\beta$ delays cell division and potentiates the effect of docetaxel on cancer cell growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 472.	8.6	14
12	Autoregulation of Class II Alpha PI3K Activity by Its Lipid-Binding PX-C2 Domain Module. <i>Molecular Cell</i> , 2018, 71, 343-351.e4.	9.7	41
13	Cytokinetic Abscission: Phosphoinositides and ESCRT Direct the Final Cut. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3561-3568.	2.6	15
14	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 $\beta$ Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	16.8	69
15	Phosphoinositide 3-Kinase-C2 $\beta$ Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1135-1144.	6.1	47
16	PI3K-C2 $\beta$ regulates Polycystin-2 ciliary entry to prevent kidney cyst formation. <i>Cilia</i> , 2015, 4, .	1.8	0
17	<i>In Vivo</i> Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. <i>Cancer Discovery</i> , 2015, 5, 740-751.	9.4	86
18	PI3K Class II $\beta$ Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function. <i>Developmental Cell</i> , 2014, 28, 647-658.	7.0	177

#	ARTICLE	IF	CITATIONS
19	PI3K/AKT signaling pathway and cancer: an updated review. <i>Annals of Medicine</i> , 2014, 46, 372-383.	3.8	887
20	Methods to Measure the Enzymatic Activity of PI3Ks. <i>Methods in Enzymology</i> , 2014, 543, 115-140.	1.0	14
21	Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. <i>Nature</i> , 2013, 499, 233-237.	27.8	362
22	Targeting PI3K in Cancer: Any Good News?. <i>Frontiers in Oncology</i> , 2013, 3, 108.	2.8	87